Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS
Saeed Sadeghi, MD, discusses the differing mechanisms of action between luspatercept and epoetin alfa, highlighting how these differences may correlate with clinical benefits for patients with lower-risk myelodysplastic syndromes (LR-MDS).
Video content above is prompted by the following:
Please discuss how the mechanism of action differs between luspatercept and epoetin alfa and how it may correlate with clinical benefit for patients with LR-MDS.
Related Content
